

Product Specification Sheet

**Angiotensin II Type 2 Receptor (AT2) Antibodies**

<input type="checkbox"/> <b>Cat. AT21-S</b>	Rabbit Anti-Human AT2 Antiserum #1	<b>SIZE:</b> 100 ul
<input type="checkbox"/> <b>Cat. AT21-A</b>	Rabbit Anti-Human AT2 IgG #1, affinity pure	<b>SIZE:</b> 100 ug
<input type="checkbox"/> <b>Cat. AT21-BTN</b>	Rabbit Anti-Human AT2 IgG-Biotinylated	<b>SIZE:</b> 50 ug
<input type="checkbox"/> <b>Cat. AT21-P</b>	Human AT2 control/blocking peptide # 2	<b>SIZE:</b> 100 ug

Angiotensin II mediates its action by interacting with membrane receptor, Angiotensin II type 1 receptors. The signal is transmitted via G-proteins that activates a phosphatidylinositol-calcium second messenger system. ATII receptors are integral membrane proteins of approx. 359-363 AA and predicted to contain at least 7 transmembrane domains. The N and C-terminus are predicted to extracellular and cytoplasmic, respectively. Three isoforms of ATII receptors have been cloned. In rat type 1a (359 aa) is expressed in the liver kidney, aorta, lung, uterus, ovary, spleen, heart, adrenal and vascular smooth muscles (1). Rat Type 1b (also known as AT3; 359 aa) is found in liver, kidney, and aorta (2). Type 1c (177 aa) has been detected in brain, kidney, liver, spleen and lung (3).

**Source of Antigen and Antibodies**

<b>Antigen</b>	18-aa peptide of human AT II type2 (gene accession # <a href="#">P50052</a> ); <b>Designated (AT21-P or control peptide)</b> conjugated to KLH, epitope location ~ C-terminal, Cytoplasmic
<b>Ab Host/type</b>	Rabbit, polyclonal Unpurified antiserum ( <b>cat #AT21-S</b> ) Aff pure IgG ( <b>cat #AT21-A</b> ) purified over antigen-agarose column
<b>Ab Format</b>	<b>Goat Anti-rabbit IgG-HRP</b> cat # 20320 (AP, biotin, FITC conjugates also available)
<b>-ve control</b>	<b>Cat # 20009-1, Rabbit</b> (non-immune) Serum IgG, purified, suitable for ELISA, Western, IHC as -ve control

**Cat# AT21-A, Biotin-conjugate**

Purified anti-AT21-A IgG was coupled to Biotin using Biotinamidocaproate N-Hydroxysuccinimide Ester (BAC) at F/P ratio ~10-20:1. The antibody is supplied in PBS, pH 7.4, 0.2% BSA and 0.05% azide in either **lyophilized** (0.1 mg) or **liquid** form (0.1 mg/0.1 ml). Reconstitute powder in PBS in 0.1 ml to prepare 1 mg/ml solution. Store at -20oC in suitable aliquots. Stability is ~6-12 months. Do not freeze and thaw.

Suggested conjugate dilutions are 1:5,000-1:30,000 ELISA, 1:2K-1:10K for western.

**Form & Storage of Antibodies/Peptide Control**

**Antiserum (unpurified)**

100ul  solution  lyophilized powder  
Supplied in Buffer: 0.05% azide  
**Reconstitute** powder in 100 ul PBS

**Affinity pure IgG**

100 ug/100ul  solution  lyophilized powder  
Supplied in **Buffer:** PBS+0.1% BSA  
**Reconstitute powder** in PBS at 1mg/ml

**Control/blocking peptide**

100 ug/100 ul  solution  lyophilized powder  
Supplied in Buffer: PBS pH 7.5,  
**Reconstitute powder in PBS at 1 mg/ml.**

**Storage**

**Short-term:** unopened, undiluted liquid vials at -20oC and powder at 4oC or -20oC..

**Long-term:** at -20C or below in suitable aliquots after reconstitution. Do not freeze and thaw and store working, diluted solutions.

**Stability:** 6-12 months at -20oC or below.

**Shipping:** 4oC for solutions and room temp for powder

**Recommended Usage**

**Western Blotting** (1:1K-5K for neat serum and 1-10 ug/ml for affinity pure using Chemiluminescence technique. (refs 2)

**ELISA** (1:10K-1:100K; using 50-100 ng of control peptide/well).

**Histochemistry & Immunofluorescence:** see refs in 2.

**Specificity & Cross-reactivity**

The 18 AA human AT21-P immunogenic peptide is 100% homologous in rabbit, 88% identical in rat and 83% with mouse AT2 receptors. It has no sequence homology with ATII type 1 or other G-protein coupled receptors. The antibodies have been shown to be specific for ATII, type 2 as shown by the expression of the ATII, type 1 and 2 and detection with antibodies (see refs 2). Antibody cross-reactivity in various species has not been studied. Control peptide, because of its low mol. Wt (<3 kDa), is not suitable for Western. It should be used for ELISA or antibody blocking experiments (use 5-10 ug control peptide per 1 ug of aff pure IgG or 1 ul antiserum) to confirm antibody specificity (see detailed protocol at: [www.4adi.com/data/abblock.html](http://www.4adi.com/data/abblock.html)).

**General References:** (1) Martin MM et al (1995) BBRC 209, 554-562; Chassagne C et al (1995) Genomics 25, 601-603; Koike G et al (1994) BBRC 203, 1842-50; Tsuzuki S et al (1994) BBRC 200, 1449-54; Martin MM et al (1994) BBRC 205, 645-651; Lazard D et al (1994) Receptor Channels 2, 271-280.

**(2) Citations of ADI's Antibodies for AT2**

Stewart JA, 2006, Journal of Molecular and Cellular Cardiology, 41, 97-107, WB, Jin X-Q, 2002, Hypertension. ;39:1021, WB; Fritzt RD, 2005, BBRC 338, 1906-1912, WB.; Rodriguez-Iturbe B, 2001, Kidney Intl. 59, 6, 2222, , IHC; Su J-Z, 2002, Hypertension : 40(6):853-8., WB; Fritz RD, 2006, BBRC 338, 1906-1912, WB, Nadal JA, 2002, Am. J. Physiol 282, H739-H748, WB

\*This product is for in vitro research use only.

AT21-S-A-P-BTN

71115A

**India Contact:**

**Life Technologies (India) Pvt. Ltd.**

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi - 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444  
Email: [customerservice@lifetechindia.com](mailto:customerservice@lifetechindia.com) Website: [www.lifetechindia.com](http://www.lifetechindia.com)